Vaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average - Here's What Happened

Key Points

• Vaxart, Inc. shares fell below their 200-day moving average of $0.41, trading as low as $0.34 during recent sessions.
• The company's current market capitalization is $78.60 million, with a PE ratio of -1.27 and a beta of 1.39.
• Institutional investors have shown interest in Vaxart, with several funds acquiring significant stakes in the company recently.

Vaxart, Inc. (NASDAQ:VXRT - ) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.41 and traded as low as $0.34. Vaxart shares last traded at $0.34, with a volume of 534,835 shares changing hands.

Vaxart Stock Performance

The company has a market cap of $78.60 million, a PE ratio of -1.27 and a beta of 1.39. The stock has a fifty day moving average of $0.37 and a 200-day moving average of $0.41.

Institutional Investors Weigh In On Vaxart

Several hedge funds have recently made changes to their positions in VXRT. Marshall Wace LLP purchased a new stake in shares of Vaxart in the 2nd quarter worth $794,000. Jones Financial Companies Lllp lifted its holdings in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after buying an additional 478,111 shares during the period. Virtu Financial LLC purchased a new stake in shares of Vaxart in the 1st quarter worth $56,000. Goldman Sachs Group Inc. purchased a new stake in shares of Vaxart in the 1st quarter worth $31,000. Finally, Creative Planning purchased a new stake in shares of Vaxart in the 2nd quarter worth $33,000. 18.05% of the stock is currently owned by hedge funds and other institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.